Sunday July 3, 2022
اردو
Dialogue Pakistan Dialogue Pakistan
Dialogue Pakistan Dialogue Pakistan
  • Citizen Journalism
  • Pakistan
  • World
  • Sports
  • Entertainment
  • Videos
    • Feature Videos
    • In House Videos
    • Mobile Footage
    • Documentaries
  • More
    • Features
    • Health
    • Sci-Tech
    • Business
    • In Pictures
    • Facebook
News

No benefit from hydroxychloroquine for covid-19: UK trial

by Web Desk June 6, 2020

AA

 No benefit from hydroxychloroquine for covid-19: UK trial

A major British clinical trial found that hydroxychloroquine has “no benefit” to patients hospitalized with COVID-19, scientists said Friday in the first large-scale study at the center of political and scientific controversy to provide results for a drug.

Hydroxychloroquine, a decades-old medicine for malaria and rheumatoid arthritis, has been hailed by high-profile figures, including US President Donald Trump, as a possible treatment for the new coronavirus, and has been included in several randomized clinical trials.

Recovery study at the University of Oxford, the largest of these to come up with results, said it will now avoid recruiting patients for hydroxychloroquine “with immediate effect.”

“Our conclusion is that this treatment does not reduce the risk of dying from COVID among hospital patients and that clearly has a significant importance for the way patients are treated, not only in the UK, but all around the world,” said Martin Landray, an Oxford professor of medicine and epidemiology who co-leads the study.

The randomized clinical trial — considered the clinical research gold standard — has enrolled a total of 11,000 patients from 175 hospitals in the UK to test a variety of new therapies.

Certain medications that are still being studied include: the combination of HIV antivirals Lopinavir and Ritonavir; a low dose of Dexamethasone steroid, usually used to minimize inflammation; Azithromycin antibiotic; and Tocilizumab anti-inflammatory medication.

Researchers are now studying convalescent plasma from the blood of people recovering from COVID-19, which includes antibodies to counter the virus.

They said 1,542 patients were randomly assigned to hydroxychloroquine, compared with 3,132 standard hospital-only patients.

After 28 days between the two groups they found “no substantial difference” in mortality, and no evidence that opioid treatment shortens the amount of time spent in hospital.

“This is a really important result, at last providing unequivocal evidence that hydroxychloroquine is of no value in the treatment of patients hospitalized with COVID-19,” said Peter Openshaw, a professor at Imperial College London, in reaction to the results.

He noted that the medication was “very dangerous” and patients would profit from suspending the trials.

Hydroxychloroquine has been in use for years but it has many potentially dangerous side effects, including heart arrhythmia.

Post Views: 103

Share This:

Tags: coronavirus hydroxychloroquine
Previous post
Next post




Polls

Should the release of foreign movies be delayed to help support Pakistani cinema?

View Results

Loading ... Loading ...
Most Recent
In House Videos

People’s Bus Service – Cost, Routes and

July 2, 2022
Feature Videos

What is the IMF deal and who’s

July 2, 2022
In House Videos

Trailer launch of the most awaited film

July 2, 2022
World

Indian flight makes emergency landing after smoke

July 2, 2022
July 2022
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Jun    
Related Stories for you

Karachi’s Covid-19 positivity ratio exceeds 21%

June 23, 2022

Karachi is witnessing an alarming surge in coronavirus cases by the Omicron variants BA4 and BA5 with positivity rate reaching

Government announces lifting of all Covid-19 restrictions in the country

March 16, 2022

ISLAMABAD: The government has announced the lifting of all sanctions imposed to control the spread of Corona Virus in the

covid

Corona’s strength began to wane in the country

February 15, 2022

Corona-positive cases are declining rapidly across the country.  According to the Ministry of National Health Services, the rate of corona

Dialogue Pakistan

Citizen Journalism is the collection, dissemination and analysis of news by the people for the people especially by the means of internet. Dialogue Pakistan is the country’s first citizen journalism portal to provide Pakistanis an opportunity to get themselves heard aiming to encourage citizen journalism inculcated with ethical values.

Quick Links

اردو
About Us
Advertise
Careers
Contact

Category

Citizen Journalism
Pakistan
World
Sports
Entertainment
Features

Download our APP

Social Platforms

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • Youtube
Copyright 2022.Dialogue Pakistan. All Rights Reserved.